Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins - PubMed (original) (raw)

Clinical Trial

Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins

Michael G Dodds et al. Cancer Immunol Immunother. 2009 Jun.

Abstract

Purpose: Recombinant interleukin-21 (rIL-21) is an immune stimulating cytokine recently tested in two Phase 1 trials for immune responsive cancers. A secondary objective of these trials was to characterize pharmacodynamic responses to rIL-21 in patients. Here, we report the effects of systemic rIL-21 on serum markers of immune stimulation.

Experimental design: Recombinant IL-21 was administered by intravenous bolus injection at dose levels from 1 to 100 microg/kg using two distinct treatment regimens: thrice weekly ('3/w') for 6 weeks; or once daily for five consecutive days followed by nine dose-free days ('5 + 9'). In the absence of dose limiting toxicity, additional cycles of dosing were initiated immediately following the nine dose-free days. An array of 70 different proteins was profiled in subject serum samples from several time points during the course of the study. Hierarchical clustering analysis was performed on a normalized subset of these data.

Results: Systemic administration of rIL-21 affected the serum levels of several cytokines, chemokines, acute-phase proteins and cell adhesion proteins. The magnitude and duration of response were dose dependent for a subset of these biomarkers. The 5 + 9 dosing regimen generally produced cyclic changes that were of greater magnitude, as compared to a more chronic stimulation with the 3/w dosing regimen. Despite these differences, rIL-21 effects on many analytes were similar between regimens when averaged over the time of treatment. Based on similar temporal, between-subject and dose response changes, groups of analytes were identified that exhibited distinct components of the rIL-21-mediated immune activation. Biomarkers indicative of lymphocyte activation (increased IL-16, decreased RANTES), acute phase response (increased CRP, ferritin), myeloid activation (increased MDC, MIP-1 alpha), and leukocyte chemotaxis/trafficking (increased sCAMs, MCP-1) were strongly modulated in subjects treated with rIL-21.

Conclusions: Administration of rIL-21 resulted in activation of multiple cell types and immune response pathways. The changes observed in serum proteins were consistent with coincident processes of lymphoid and myeloid cell activation and trafficking, and acute phase response.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Changes in serum concentrations of sTNFRII (a), and IL-18 (b). Mean change from baseline (±SD) on Day 19 of treatment is shown for each rIL-21 treatment cohort

Fig. 2

Fig. 2

Changes in serum concentration relative to baseline for selected analytes in subjects treated with 30 μg/kg rIL-21. Effects of the different dose regimens, 5 + 9 (dashed line) and 3/w (solid line), are compared

Fig. 3

Fig. 3

Dendrogram of the distance measures (unweighted average Pearson correlation coefficient between the members of linked cluster) of the serum markers for each Subject treated with 30 μg/kg rIL-21 on the 5 + 9 regimen

Fig. 4

Fig. 4

Group average percent change from group average baseline (_y_-axis, %) over time (_x_-axis, days) for serum markers grouped in clusters identified in Fig. 3 for Subjects treated with 30 μg/kg rIL-21 on the 5 + 9 regimen (n = 12)

Similar articles

Cited by

References

    1. Alonso R, et al. Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res. 2005;15(1):53–60. doi: 10.1097/00008390-200502000-00009. - DOI - PubMed
    1. Carson WE, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99(5):937–943. doi: 10.1172/JCI119258. - DOI - PMC - PubMed
    1. Damle NK, Doyle LV. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J Immunol. 1989;142(8):2660–2669. - PubMed
    1. Davis ID, et al. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res. 2007;13(23):6926–6932. doi: 10.1158/1078-0432.CCR-07-1238. - DOI - PubMed
    1. Davis ID, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007;13(12):3630–3636. doi: 10.1158/1078-0432.CCR-07-0410. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources